Virax Biolabs Group Limited (NASDAQ: VRAX) announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia.

Under the agreement, Virax will supply its ImmuneSelect research-use-only immune profiling product line, including ELISpot assay plates used to measure cellular immune responses, to Fosun Diagnostics under purchase orders. Exclusivity is subject to agreed minimum purchase and performance requirements. Pricing includes volume-based tiers. The initial focus is tuberculosis-related research applications in Thailand, with planned rollout across the other five markets.

ImmuneSelect is distinct from ViraxImmune, the company's diagnostic platform currently in clinical and regulatory development.

The agreement framework also includes provisions for additional product offerings, higher-volume supply arrangements, and potential OEM or private-label arrangements.

Fosun Diagnostics is the core diagnostics entity under Fosun Medtech, a division of Fosun Pharma, which is listed on the Shanghai Stock Exchange (600196.SH) and the Hong Kong Stock Exchange (02196.HK). Fosun Pharma reported 2025 revenue of RMB41.662 billion, approximately $5.8 billion.

"This agreement represents a major step forward in the commercial rollout of our ImmuneSelect platform across Southeast Asia," said James Foster, Chairman and Chief Executive Officer of Virax Biolabs.

Leon Zhang, International Commercial Head for China Domestic Business at Fosun MedTech, said the company looks forward to "assessing its performance across multiple regional markets."